Langerhans cells as targets for immunotherapy against skin cancer

Immunology and Cell Biology

Volumn 88, Issue 4, 2010, Pages 431-437

  Stoitzner, Patrizia ^a   Sparber, Florian ^a   Tripp, Christoph H ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Immunotherapy; Langerhans cells; Skin immunology

Indexed keywords

AGGRIPAL; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; ESCHERICHIA COLI ENTEROTOXIN; GLYCOPROTEIN GP 100; HLA ANTIGEN CLASS 1; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LANGERIN; MELANOMA ANTIGEN; OVALBUMIN; PROTEIN E7; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MIGRATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNOMODULATION; LANGERHANS CELL; LYMPHOCYTE HOMING; LYMPHOCYTIC INFILTRATION; MELANOMA; NATURAL KILLER T CELL; NONHUMAN; PATCH TEST; REVIEW; SKIN ALLERGY; SKIN CANCER; SKIN STRUCTURE; SKIN TUMOR; TRAVELLER DIARRHEA; TUMOR IMMUNITY;

ANIMALS; HUMANS; IMMUNOTHERAPY; LANGERHANS CELLS; SKIN NEOPLASMS;

EID: 77952222437     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.31     Document Type: Review

References (96)

1. Romani N, Clausen B, Stoitzner P. Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol Rev 2010; 234: 120-141.
2. Poulin LF, Henri S, de Bovis B, Devilard E, Kissenpfennig A, Malissen B. The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cells. J Exp Med 2007; 204: 3119-3131.
3. Ginhoux F, Collin MP, Bogunovic M, Abel M, Leboeuf M, Helft J et al. Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state. J Exp Med 2007; 204: 3133-3146.
4. Bursch LS, Wang L, Igyarto B, Kissenpfennig A, Malissen B, Kaplan DH et al. Identification of a novel population of Langerin+ dendritic cells. J Exp Med 2007; 204: 3147-3156.
5. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15: 138-147.
6. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P et al. Rapid induction of tumor-specific type 1T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195: 1279-1288.
7. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220: 129-150.
8. Stoitzner P, Green LK, Jung JY, Price KM, Tripp CH, Malissen B et al. Tumor immunotherapy by epicutaneous immunization requires langerhans cells. J Immunol 2008; 180: 1991-1998.
9. Bynoe MS, Evans JT, Viret C, Janeway Jr CA. Epicutaneous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis. Immunity 2003; 19: 317-328.
10. Nikolic WV, Bai Y, Obregon D, Hou H, Mori T, Zeng J et al. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci USA 2007; 104: 2507-2512.
11. Seo N, Tokura Y, Nishijima T, Hashizume H, Furukawa F, Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc Natl Acad Sci USA 2000; 97: 371-376.
12. Yagi H, Hashizume H, Horibe T, Yoshinari Y, Hata M, Ohshima A et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer Res 2006; 66: 10136-10144.
13. Dell K, Koesters R, Gissmann L. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus- induced tumors. Int J Cancer 2006; 118: 364-372.
14. Hosoi A, Takeda Y, Furuichi Y, Kurachi M, Kimura K, Maekawa R et al. Memory Th1 cells augment tumor-specific CTL following transcutaneous peptide immunization. Cancer Res 2008; 68: 3941-3949.
15. Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 1998; 161: 3211-3214.
16. Hammond SA, Walwender D, Alving CR, Glenn GM. Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine 2001; 19: 2701-2707.
17. Beignon AS, Briand JP, Muller S, Partidos CD. Immunization onto bare skin with heatlabile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology 2001; 102: 344-351.
18. Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008; 371: 2019-2025.
19. Vogt A, Mahe B, Costagliola D, Bonduelle O, Hadam S, Schaefer G et al. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8T cell immune responses in humans. J Immunol 2008; 180: 1482-1489.
20. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 2004; 113: 998-1007.
21. Romani N, Koide S, Crowley M, Witmer-Pack M, Livingstone AM, Fathman CG et al. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 1989; 169: 1169-1178.
22. Schuler G, Steinman RM. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 1985; 161: 526-546. (Pubitemid 15142803)
23. Ratzinger G, Baggers J, de Cos MA, Yuan J, Dao T, Reagan JL et al. Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J Immunol 2004; 173: 2780-2791.
24. Cao T, Ueno H, Glaser C, Fay JW, Palucka AK, Banchereau J. Both Langerhans cells and interstitial DC cross-present melanoma antigens and efficiently activate antigenspecific CTL. Eur J Immunol 2007; 37: 2657-2667.
25. Fay JW, Palucka AK, Paczesny S, Dhodapkar M, Johnston DA, Burkeholder S et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother 2006; 55: 1209-1218.
26. Grabbe S, Bruvers S, Gallo RL, Knisely TL, Nazareno R, Granstein RD. Tumor antigen presentation by murine epidermal cells. J Immunol 1991; 146: 3656-3661.
27. Eggert AO, Becker JC, Ammon M, McLellan AD, Renner G, Merkel A et al. Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture. Eur J Immunol 2002; 32: 122-127.
28. Stoitzner P, Tripp CH, Eberhart A, Price KM, Jung JY, Bursch L et al. Langerhans cells cross-present antigen derived from skin. Proc Natl Acad Sci USA 2006; 103: 7783-7788.
29. Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000; 12: 71-81.
30. Valladeau J, Clair-Moninot V, Dezutter-Dambuyant C, Pin JJ, Kissenpfennig A, Mattei MG et al. Identification of mouse langerin/CD207 in Langerhans cells and some dendritic cells of lymphoid tissues. J Immunol 2002; 168: 782-792.
31. Stoitzner P, Holzmann S, McLellan AD, Ivarsson L, Stossel H, Kapp M et al. Visualization and characterization of migratory Langerhans cells in murine skin and lymph nodes by antibodies against Langerin/CD207. J Invest Dermatol 2003; 120: 266-274.
32. Bennett CL, van Rijn E, Jung S, Inaba K, Steinman RM, Kapsenberg ML et al. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 2005; 169: 569-576.
33. Kissenpfennig A, Henri S, Dubois B, Laplace-Builhe C, Perrin P, Romani N et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 2005; 22: 643-654.
34. Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ. Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 2005; 23: 611-620.
35. Igyarto BZ, Jenison MC, Dudda JC, Roers A, Muller W, Koni PA et al. Langerhans cells suppress contact hypersensitivity responses via cognate CD4 interaction and langerhans cell-derived IL-10. J Immunol 2009; 183: 5085-5093.
36. Kaplan DH, Kissenpfennig A, Clausen BE. Insights into Langerhans cell function from Langerhans cell ablation models. Eur J Immunol 2008; 38: 2369-2376.
37. Wang L, Bursch LS, Kissenpfennig A, Malissen B, Jameson SC, Hogquist KA. Langerin expressing cells promote skin immune responses under defined conditions. J Immunol 2008; 180: 4722-4727.
38. Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, Caminschi I et al. Crosspresentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol 2009; 10: 488-495.
39. Ruedl C, Koebel P, Bachmann M, Hess M, Karjalainen K. Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes. J Immunol 2000; 165: 4910-4916.
40. Kamath AT, Henri S, Battye F, Tough DF, Shortman K. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 2002; 100: 1734-1741.
41. Henri S, Vremec D, Kamath A, Waithman J, Williams S, Benoist C et al. The dendritic cell populations of mouse lymph nodes. J Immunol 2001; 167: 741-748.
42. Itano AA, McSorley SJ, Reinhardt RL, Ehst BD, Ingulli E, Rudensky AY et al. Distinct dendritic cell populations sequentially present antigen to CD4T cells and stimulate different aspects of cell-mediated immunity. Immunity 2003; 19: 47-57.
43. Allenspach EJ, Lemos MP, Porrett PM, Turka LA, Laufer TM. Migratory and lymphoidresident dendritic cells cooperate to efficiently prime naive CD4T cells. Immunity 2008; 29: 795-806.
44. Tripp CH, Sparber F, Hermans IF, Romani N, Stoitzner P. Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells. J Immunol 2009; 182: 7644-7654.
45. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 2005; 174: 2476-2480.
46. Stoitzner P, Tripp CH, Douillard P, Saeland S, Romani N. Migratory Langerhans cells in mouse lymph nodes in steady state and inflammation. J Invest Dermatol 2005; 125: 116-125.
47. Le Gal FA, Widmer VM, Dutoit V, Rubio-Godoy V, Schrenzel J, Walker PR et al. Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors. J Invest Dermatol 2007; 127: 622-629.
48. Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 2002; 195: 135-141.
49. Dudda JC, Simon JC, Martin S. Dendritic cell immunization route determines CD8+ T cell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets. J Immunol 2004; 172: 857-863.
50. Bianchi T, Pincus LB, Wurbel MA, Rich BE, Kupper TS, Fuhlbrigge RC et al. Maintenance of peripheral tolerance through controlled tissue homing of antigenspecific T cells in K14-mOVA mice. J Immunol 2009; 182: 4665-4674.
51. Chang SY, Cha HR, Igarashi O, Rennert PD, Kissenpfennig A, Malissen B et al. Cutting edge: Langerin+ dendritic cells in the mesenteric lymph node set the stage for skin and gut immune system cross-talk. J Immunol 2008; 180: 4361-4365.
52. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000; 6: 1403-1406.
53. Mahe B, Vogt A, Liard C, Duffy D, Abadie V, Bonduelle O et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol 2009; 129: 1156-1164.
54. Streilein JW, Lonsberry LW, Bergstresser PR. Depletion of epidermal langerhans cells and Ia immunogenicity from tape-stripped mouse skin. J Exp Med 1982; 155: 863-871.
55. Holzmann S, Tripp CH, Schmuth M, Janke K, Koch F, Saeland S et al. A model system using tape stripping for characterization of Langerhans cell-precursors in vivo. J Invest Dermatol 2004; 122: 1165-1174.
56. Wood LC, Jackson SM, Elias PM, Grunfeld C, Feingold KR. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J Clin Invest 1992; 90: 482-487.
57. Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol 1994; 30: 535-546.
58. Nishijima T, Tokura Y, Imokawa G, Seo N, Furukawa F, Takigawa M. Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. J Invest Dermatol 1997; 109: 175-182.
59. Frerichs DM, Ellingsworth LR, Frech SA, Flyer DC, Villar CP, Yu J et al. Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine 2008; 26: 2782-2787.
60. Chen D, Endres RL, Erickson CA, Weis KF, McGregor MW, Kawaoka Y et al. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat Med 2000; 6: 1187-1190.
61. Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002; 8: 415-419.
62. Ng KW, Pearton M, Coulman S, Anstey A, Gateley C, Morrissey A et al. Development of an ex vivo human skin model for intradermal vaccination: tissue viability and Langerhans cell behaviour. Vaccine 2009; 27: 5948-5955.
63. Zhao YL, Murthy SN, Manjili MH, Guan LJ, Sen A, Hui SW. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. Vaccine 2006; 24: 1282-1290.
64. Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature 1998; 391: 851.
65. Kahlon R, Hu Y, Orteu CH, Kifayet A, Trudeau JD, Tan R et al. Optimization of epicutaneous immunization for the induction of CTL. Vaccine 2003; 21: 2890-2899.
66. Lebre MC, van der Aar AM, van Baarsen L, van Capel TM, Schuitemaker JH, Kapsenberg ML et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 2007; 127: 331-341.
67. Flacher V, Bouschbacher M, Verronese E, Massacrier C, Sisirak V, Berthier-Vergnes O et al. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol 2006; 177: 7959-7967.
68. van der Aar AM, Sylva-Steenland RM, Bos JD, Kapsenberg ML, de Jong EC, Teunissen MB. Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol 2007; 178: 1986-1990.
69. Sugita K, Kabashima K, Atarashi K, Shimauchi T, Kobayashi M, Tokura Y. Innate immunity mediated by epidermal keratinocytes promotes acquired immunity involving Langerhans cells and T cells in the skin. Clin Exp Immunol 2007; 147: 176-183.
70. Mitsui H, Watanabe T, Saeki H, Mori K, Fujita H, Tada Y et al. Differential expression and function of toll-like receptors in Langerhans cells: comparison with splenic dendritic cells. J Invest Dermatol 2004; 122: 95-102.
71. Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H. Protective roles of mast cells against enterobacterial infection are mediated by toll-like receptor 4. J Immunol 2001; 167: 2250-2256.
72. Matsushima H, Yamada N, Matsue H, Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol 2004; 173: 531-541.
73. Pegu A, Qin S, Fallert Junecko BA, Nisato RE, Pepper MS, Reinhart TA. Human lymphatic endothelial cells express multiple functional TLRs. J Immunol 2008; 180: 3399-3405.
74. Miller LS, Modlin RL. Toll-like receptors in the skin. Semin Immunopathol 2007; 29: 15-26.
75. Inoue J, Aramaki Y. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG- oligodeoxynucleotides. Vaccine 2007; 25: 1007-1013.
76. Wang LF, Hsu CJ, Miaw SC, Chiu HC, Liu CY, Yu HS. Cross-priming with an epicutaneously introduced soluble protein antigen generates Tc1 cells. Eur J Immunol 2006; 36: 2904-2911.
77. Beignon AS, Briand JP, Muller S, Partidos CD. Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells. Immunology 2002; 105: 204-212.
78. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-141.
79. Heib V, Becker M, Warger T, Rechtsteiner G, Tertilt C, Klein M et al. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood 2007; 110: 946-953.
80. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW et al. Tumorspecific CD4+ T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. J Immunol 2000; 165: 6047-6055.
81. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7: 790-802.
82. Idoyaga J, Cheong C, Suda K, Suda N, Kim JY, Lee H et al. Cutting edge: langerin/ CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. J Immunol 2008; 180: 3647-3650.
83. Carter RW, Thompson C, Reid DM, Wong SY, Tough DF. Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J Immunol 2006; 177: 2276-2284.
84. Flacher V, Sparber F, Tripp CH, Romani N, Stoitzner P. Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy. Cancer Immunol Immunother 2009; 58: 1137-1147.
85. Flacher V, Tripp CH, Stoitzner P, Haid B, Ebner S, Del Frari B et al. Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis. J Invest Dermatol 2010; 130: 755-762.
86. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769-779.
87. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199: 815-824.
88. Wang LF, Lin JY, Hsieh KH, Lin RH. Epicutaneous exposure of protein antigen induces a predominant Th2-like response with high IgE production in mice. J Immunol 1996; 156: 4077-4082.
89. Herrick CA, MacLeod H, Glusac E, Tigelaar RE, Bottomly K. Th2 responses induced by epicutaneous or inhalational protein exposure are differentially dependent on IL-4. J Clin Invest 2000; 105: 765-775.
90. Strid J, Hourihane J, Kimber I, Callard R, Strobel S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol 2004; 34: 2100-2109.
91. He R, Oyoshi MK, Jin H, Geha RS. Epicutaneous antigen exposure induces a Th17 response that drives airway inflammation after inhalation challenge. Proc Natl Acad Sci USA 2007; 104: 15817-15822.
92. Ghoreishi M, Dutz JP. Tolerance induction by transcutaneous immunization through ultraviolet-irradiated skin is transferable through CD4+CD25+ T regulatory cells and is dependent on host-derived IL-10. J Immunol 2006; 176: 2635-2644.
93. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
94. Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008; 29: 497-510.
95. Banchereau J, Klechevsky E, Schmitt N, Morita R, Palucka K, Ueno H. Harnessing human dendritic cell subsets to design novel vaccines. Ann N Y Acad Sci 2009; 1174: 24-32.
96. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711.